Literature DB >> 9878639

Increased frequency of genetic thrombophilia in women with complications of pregnancy.

M J Kupferminc1, A Eldor, N Steinman, A Many, A Bar-Am, A Jaffa, G Fait, J B Lessing.   

Abstract

BACKGROUND: Obstetrical complications such as severe preeclampsia, abruptio placentae, fetal growth retardation, and stillbirth are associated with intervillous or spiral-artery thrombosis and inadequate placental perfusion. Whether these complications are associated with an increased frequency of thrombophilic mutations is not known.
METHODS: We studied 110 women who had one of the above-mentioned obstetrical complications and 110 women who had one or more normal pregnancies. The women were tested several days after delivery for the mutation of guanine to adenine at nucleotide 1691 [corrected] in the factor V gene (factor V Leiden), the mutation of cytosine to thymine at nucleotide 677 in the gene encoding methylenetetrahydrofolate reductase, and the mutation of guanine to adenine at nucleotide 20210 in the prothrombin gene. Two to three months after delivery the women were tested for deficiency of protein C, protein S, or antithrombin III and for the presence of anticardiolipin antibodies.
RESULTS: The mutation at nucleotide 1691 [corrected] in the factor V gene was detected in 22 of the women with obstetrical complications and in 7 of the women with normal pregnancies (20 percent and 6 percent, respectively; P=0.003). Twenty-four women with complications, as compared with nine women without complications, were homozygous for the C677T mutation in the gene encoding methylenetetrahydrofolate reductase (22 percent and 8 percent, respectively; P=0.005). The G20210A mutation in the prothrombin gene was found in 11 women with complications as compared with 3 women without complications (10 percent and 3 percent, respectively; P=0.03). Overall, 57 women with obstetrical complications had a thrombophilic mutation, as compared with 19 women with normal pregnancies (52 percent and 17 percent, respectively; P<0.001). Deficiency of protein S, protein C, or antithrombin III or anticardiolipin antibodies were detected in an additional 14 women with complications, as compared with 1 woman with a normal pregnancy (13 percent and 1 percent, respectively; P<0.001).
CONCLUSIONS: Women with serious obstetrical complications have an increased incidence of mutations predisposing them to thrombosis and other inherited and acquired forms of thrombophilia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9878639     DOI: 10.1056/NEJM199901073400102

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  95 in total

Review 1.  [Angiology update].

Authors:  C Ranke; H J Trappe
Journal:  Med Klin (Munich)       Date:  1999-05-15

Review 2.  The impact of molecular medicine upon early cardiovascular drug development.

Authors:  M W Lunnon; M Braddock
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

3.  The Jeremiah Metzger Lecture. Hypercoagulable states: challenges and opportunities.

Authors:  R L Nachman
Journal:  Trans Am Clin Climatol Assoc       Date:  2001

4.  Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis.

Authors:  Sassan HajMohammadi; Keiichi Enjyoji; Marc Princivalle; Patricia Christi; Miroslav Lech; David Beeler; Helen Rayburn; John J Schwartz; Samad Barzegar; Ariane I de Agostini; Mark J Post; Robert D Rosenberg; Nicholas W Shworak
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 5.  Pathophysiology and maternal biologic markers of preeclampsia.

Authors:  Jacques Massé; Yves Giguère; Abdelaziz Kharfi; Joël Girouard; Jean-Claude Forest
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

6.  Risk of subsequent thromboembolism for patients with pre-eclampsia.

Authors:  Carl van Walraven; Muhammad Mamdani; Adam Cohn; Yasir Katib; Mark Walker; Marc A Rodger
Journal:  BMJ       Date:  2003-04-12

7.  Alexia without agraphia in a postpartum eclamptic patient with factor V Leiden deficiency.

Authors:  Haideh Yazdani Sabet; Pamela Blake; Dan Nguyen
Journal:  AJNR Am J Neuroradiol       Date:  2004-03       Impact factor: 3.825

Review 8.  Mice deficient in heparan sulfate 3-O-sulfotransferase-1: normal hemostasis with unexpected perinatal phenotypes.

Authors:  Nicholas W Shworak; Sassan HajMohammadi; Ariane I de Agostini; Robert D Rosenberg
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

9.  Risk for early pregnancy loss by factor XIII Val34Leu: the impact of fibrinogen concentration.

Authors:  Astrid Dossenbach-Glaninger; Mick van Trotsenburg; Christian Oberkanins; Johanna Atamaniuk
Journal:  J Clin Lab Anal       Date:  2013-11       Impact factor: 2.352

Review 10.  Low-molecular-weight heparins during pregnancy.

Authors:  Ariel Many; Gideon Koren
Journal:  Can Fam Physician       Date:  2005-02       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.